These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

42 related articles for article (PubMed ID: 21178445)

  • 1. Ozonation of human HIV-infected plasmas for producing a global vaccine: How HIV-patients may help fight the HIV pandemia.
    Bocci V; Zanardi I; Travagli V
    Virulence; 2010; 1(3):215-7. PubMed ID: 21178445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV vaccine efficacy trials: towards the future of HIV prevention.
    Kim D; Elizaga M; Duerr A
    Infect Dis Clin North Am; 2007 Mar; 21(1):201-17, x. PubMed ID: 17502236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A safe, effective and affordable HIV vaccine--an urgent global need.
    Joseph J; Etcheverry F; Alcami J; María GJ
    AIDS Rev; 2005; 7(3):131-8. PubMed ID: 16302460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucosal immunization with inactivated human immunodeficiency virus plus CpG oligodeoxynucleotides induces genital immune responses and protection against intravaginal challenge.
    Dumais N; Patrick A; Moss RB; Davis HL; Rosenthal KL
    J Infect Dis; 2002 Oct; 186(8):1098-105. PubMed ID: 12355360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aiming for successful vaccine-induced HIV-1-specific cytotoxic T lymphocytes.
    Yang OO
    AIDS; 2008 Jan; 22(3):325-31. PubMed ID: 18195558
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunostimulatory combinations: designing the next generation of vaccine adjuvants.
    Kornbluth RS; Stone GW
    J Leukoc Biol; 2006 Nov; 80(5):1084-102. PubMed ID: 16931603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1 immunogen (remune).
    Newsline People AIDS Coalit N Y; 1998 Dec; ():36. PubMed ID: 11367099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvanted vaccine strategies and live vector approaches for the prevention of AIDS.
    Voss G; Villinger F
    AIDS; 2000; 14 Suppl 3():S153-65. PubMed ID: 11086858
    [No Abstract]   [Full Text] [Related]  

  • 9. Clarification of how HIV-1 DNA and protein immunizations may be better used to obtain HIV-1-specific mucosal and systemic immunity.
    Hinkula J
    Expert Rev Vaccines; 2007 Apr; 6(2):203-12. PubMed ID: 17408370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of prophylactic AIDS vaccines: the current state of affairs.
    Hanke T
    Curr Opin Mol Ther; 2003 Feb; 5(1):25-32. PubMed ID: 12669467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. No vaccine against HIV yet--are we not perfectly equipped?
    Singh M
    Virol J; 2006 Aug; 3():60. PubMed ID: 16939652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of vaccination strategies that elicit broadly neutralizing antibodies against human immunodeficiency virus type 1 in both the mucosal and systemic immune compartments.
    Hone DM; DeVico AL; Fouts TR; Onyabe DY; Agwale SM; Wambebe CO; Blattner WA; Gallo RC; Lewis GK
    J Hum Virol; 2002; 5(1):17-23. PubMed ID: 12352264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current strategies and limitations of HIV vaccines.
    Kawalekar OU; Shedlock DJ; Weiner DB
    Curr Opin Investig Drugs; 2010 Feb; 11(2):192-202. PubMed ID: 20112169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine.
    Liu J; Ngai N; Stone GW; Yue FY; Ostrowski MA
    Vaccine; 2009 Aug; 27(37):5077-84. PubMed ID: 19573639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges and opportunities for development of an AIDS vaccine.
    Nabel GJ
    Nature; 2001 Apr; 410(6831):1002-7. PubMed ID: 11309631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. State of the science. HIV vaccine development.
    Grady C; Kelly G
    Nurs Clin North Am; 1996 Mar; 31(1):25-39. PubMed ID: 8604385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ex vivo production of autologous whole inactivated HIV-1 for clinical use in therapeutic vaccines.
    Gil C; Climent N; García F; Hurtado C; Nieto-Márquez S; León A; García MT; Rovira C; Miralles L; Dalmau J; Pumarola T; Almela M; Martinez-Picado J; Lifson JD; Zamora L; Miró JM; Brander C; Clotet B; Gallart T; Gatell JM
    Vaccine; 2011 Aug; 29(34):5711-24. PubMed ID: 21679735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AIDS vaccine development: the long and winding road.
    Garber DA; Feinberg MB
    AIDS Rev; 2003; 5(3):131-9. PubMed ID: 14598562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AIDS/HIV. Developing an AIDS vaccine: need, uncertainty, hope.
    Emini EA; Koff WC
    Science; 2004 Jun; 304(5679):1913-4. PubMed ID: 15218131
    [No Abstract]   [Full Text] [Related]  

  • 20. CD8+ T-cell-mediated cross-clade protection in the genital tract following intranasal immunization with inactivated human immunodeficiency virus antigen plus CpG oligodeoxynucleotides.
    Jiang JQ; Patrick A; Moss RB; Rosenthal KL
    J Virol; 2005 Jan; 79(1):393-400. PubMed ID: 15596832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.